TY  - GEN
AU  - Taal,Walter
AU  - Oosterkamp,Hendrika M
AU  - Walenkamp,Annemiek M E
AU  - Dubbink,Hendrikus J
AU  - Beerepoot,Laurens V
AU  - Hanse,Monique C J
AU  - Buter,Jan
AU  - Honkoop,Aafke H
AU  - Boerman,Dolf
AU  - de Vos,Filip Y F
AU  - Dinjens,Winand N M
AU  - Enting,Roelien H
AU  - Taphoorn,Martin J B
AU  - van den Berkmortel,Franchette W P J
AU  - Jansen,Rob L H
AU  - Brandsma,Dieta
AU  - Bromberg,Jacoline E C
AU  - van Heuvel,Irene
AU  - Vernhout,René M
AU  - van der Holt,Bronno
AU  - van den Bent,Martin J
TI  - Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
SN  - 1474-5488
PY  - 2014///1215
KW  - Administration, Oral
KW  - Adolescent
KW  - Adult
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Bevacizumab
KW  - Brain Neoplasms
KW  - mortality
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Drug Combinations
KW  - Drug Therapy, Combination
KW  - Female
KW  - Follow-Up Studies
KW  - Glioblastoma
KW  - Humans
KW  - Infusions, Intravenous
KW  - Lomustine
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Invasiveness
KW  - pathology
KW  - Neoplasm Recurrence, Local
KW  - drug therapy
KW  - Neoplasm Staging
KW  - Survival Analysis
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(14)70314-6
ER  -